Literature DB >> 10451787

Middle cerebral artery blood velocity during exercise in patients with atrial fibrillation.

K Ide1, A L Gulløv, F Pott, J J Van Lieshout, B G Koefoed, P Petersen, N H Secher.   

Abstract

Atrial fibrillation limits the ability to increase cardiac output during exercise and may, in turn, affect the exercise-associated elevation in cerebral perfusion. In nine patients with atrial fibrillation (AF) and in five age-matched healthy subjects, middle cerebral artery blood velocity (MCA Vmean) was measured during incremental exercise using the transcranial Doppler. The AF patient group exhibited a lower aerobic capacity than the control group [peak work rate: 106 W (71-153 W; median and range) vs. 129 W (118-1.9 W) and maximal oxygen uptake: 1.4 l min-1 (1.0-1.9 l min-1) vs. 1.7 l min-1 (1.4-2.2 l min-1); P = 0.05]. At rest, MCA Vmean was not significantly different between the two groups [43 cm s-1 (39-56 cm s-1) vs. 52 cm s-1 (40-68 cm s-1)]. During intense cycling, the increase in MCA Vmean was to 51 cm s-1 (40-78 cm s-1) (9%) in the AF group and lower than in the healthy subjects [to 62 cm s-1 (50-81 cm s-1) 23%; P < 0.05], which corresponded with the smaller than expected increase in cardiac output [156% (130-169%) vs. 180%]. Thus, there was a correlation between the increase in MCA Vmean and the ability to increase cardiac output (r2 = 0.55, P < 0.01). We suggest that, during exercise with a large muscle mass, atrial fibrillation affects the ability to elevate cerebral perfusion, and this results from an impaired ability to increase cardiac output.

Entities:  

Mesh:

Year:  1999        PMID: 10451787     DOI: 10.1046/j.1365-2281.1999.00178.x

Source DB:  PubMed          Journal:  Clin Physiol        ISSN: 0144-5979


  18 in total

1.  Middle cerebral artery blood velocity is reduced with hyperthermia during prolonged exercise in humans.

Authors:  L Nybo; B Nielsen
Journal:  J Physiol       Date:  2001-07-01       Impact factor: 5.182

2.  Blood flow distribution during heat stress: cerebral and systemic blood flow.

Authors:  Shigehiko Ogoh; Kohei Sato; Kazunobu Okazaki; Tadayoshi Miyamoto; Ai Hirasawa; Keiko Morimoto; Manabu Shibasaki
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-14       Impact factor: 6.200

Review 3.  A definition of normovolaemia and consequences for cardiovascular control during orthostatic and environmental stress.

Authors:  Jasper Truijen; Morten Bundgaard-Nielsen; Johannes J van Lieshout
Journal:  Eur J Appl Physiol       Date:  2010-01-07       Impact factor: 3.078

Review 4.  Cerebral changes during exercise in the heat.

Authors:  Bodil Nielsen; Lars Nybo
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

Review 5.  Cardiovascular control during whole body exercise.

Authors:  Stefanos Volianitis; Niels H Secher
Journal:  J Appl Physiol (1985)       Date:  2016-06-16

Review 6.  The impact of age on cerebral perfusion, oxygenation and metabolism during exercise in humans.

Authors:  Igor D Braz; James P Fisher
Journal:  J Physiol       Date:  2015-11-02       Impact factor: 5.182

7.  The relationship between cardiac output and dynamic cerebral autoregulation in humans.

Authors:  B M Deegan; E R Devine; M C Geraghty; E Jones; G Ólaighin; J M Serrador
Journal:  J Appl Physiol (1985)       Date:  2010-08-05

8.  The effect of changes in cardiac output on middle cerebral artery mean blood velocity at rest and during exercise.

Authors:  Shigehiko Ogoh; R Matthew Brothers; Quinton Barnes; Wendy L Eubank; Megan N Hawkins; Sushmita Purkayastha; Albert O-Yurvati; Peter B Raven
Journal:  J Physiol       Date:  2005-10-06       Impact factor: 5.182

9.  Enhanced cerebral CO2 reactivity during strenuous exercise in man.

Authors:  P Rasmussen; H Stie; B Nielsen; L Nybo
Journal:  Eur J Appl Physiol       Date:  2005-11-12       Impact factor: 3.078

10.  Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.

Authors:  Peter Nissen; Patrice Brassard; Thomas B Jørgensen; Niels H Secher
Journal:  Neurocrit Care       Date:  2010-02       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.